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Poster Session II 107are females, two males. The mean age is 42(26–60) and the mean
follow-up is 7 (3–9) years. Although tumours have not been de-
scribed in this group of donors, nevertheless the G-CSF administra-
tion in patients with Multiple Sclerosis has been frequently
correlated with a worsening of the clinical status (2,3). Moreover,
the G-CSF therapy seems to exacerbate the recurrence of autoim-
mune diseases, as described in other published surveys (4).
Taken together, these data seem to confirm and underline the
need of a long-term clinical and haematological surveillance period
of healthy subjects stimulated with G-CSF. Nevertheless, the sur-
veillance duration has not been definitely fixed: ten years of follow-
up could be a too short period to lead to significant information on
the potential induction or enhancement of pathological conditions.
Bibliography: (1): Bone Marrow Transplantation, 36: 289–294,
2005; (2): Neurology, 54: 2147–2150, 2000; (3): J Neuroimmunol,
2006; (4): Bone Marrow Transplantotion 2001; 28: 1–12.
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IMPACT OF LONGITUDINAL LONG TERM TRANSPLANT CLINIC (LTTC)
ON SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT (SCT)
Jagasia, M.1, Clifton, C.1, Vaughan, L.A.1, Chinratanalab, W.1,
Chen, H.2, Dixon, S.1, Hunt, C.1, Kassim, A.1. 1Vanderbilt University
Medical Center, Nashville, TN; 2Vanderbilt University Medical Center,
Nashville, TN.
Introduction: Allogeneic SCT patients (pts.) are followed inten-
sively for 100 days after SCT at the transplant center (TC). The
ideal model of follow-up after day 100 is not well studied. Pts. are
often transitioned back to their primary hematologist at the TC
(or in community). We hypothesized that a longitudinal LTTC su-
pervised by transplant physicians and mid-level providers and care
coordinated with consultants in other disciplines would improve
outcome. Methods: We established LTTC in 1/2006. All pts. after
allogeneic SCT (.day 100) were transitioned to LTTC (group[G]
1: transition day\120). Some pts. were transitioned after day 120 or
were referred by their primary hematologist to LTTC (G2). G3 was
a historical group of pts. with survival of at least 150 days after SCT
(care provided by primary hematologist). Overall survival (OS) was
measured from transition to LTTC for G1 and 2 and from day 150
for G3. Results: G 1, 2 and 3 had 43, 31 and 114 pts., respectively.
Groups were comparable for age at SCT, donor status, and disease
risk (CIBMTR definition). More pts. in G3 (74%) had ablative SCT
compared to G1 (51%) and G2 (65%) (P5 0.019). Median follow-
up time was different (G1: 349 days, G2: 966 days, G3: 765 days, P
\0.0001). Median OS was 1905 days (95% CI 1143–2664). The OS
for the 3 groups were different (P5 0.001). 1-yr. OS for G 1, 2 and 3
were 80%, 88%, and 59%. There were 4, 2, and 55 deaths in the 3
groups (non-relapse mortality: 0%, 50%, and 37%). In univariate
analyses (G1 1 2 vs.3), donor type (P 5 0.045), risk status (P 5
0.0012) and group status based on LTTC (time dependent variable)
(P 5 0.0478) were significant predictors of OS. Using Cox-regres-
sion analyses (adjusted for transplant age, donor type, transplant
type), risk status (low vs. high risk) (HR 2.82, P 5 0.0005) and
LTTC status (HR 1.97, P 5 0.047) were significant predictors of
OS. Using Cox-regression analyses (G1 vs. 3) risk status (low vs.
high risk) (HR 2.74, P 5 0.0012) and LTTC status (HR 3.27, P
5 0.0251) were significant predictors of OS.Conclusion:Although
limited by retrospective nature, short follow up in G1 and compar-
ision to a historical control, our study shows that pts. followed in the
LTTC clinic with coordinated care from consultants had a better
OS compared with pts. who were followed prior to LTTC being es-
tablished. The impact of LTTC clinic on other long-term trans-
plant problems (viz. diabetes, dyslipidemias, osteoporosis, sexual
dysfunction) will be studied.
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PRE-TRANSPLANT SEUM C-PEPTIDE LEVEL PREDICTS FOR POST-
TRANSPLANT DIABETES MELLITUS (PTDM) AFTER ALLOGENEIC STEM
CELL TRANSPLANT (SCT)
Jagasia, S.1, Perkins, J.1, Survant, M.1, Chen, H.2, Jagasia, M.3. 1Van-
derbilt Univeristy Medical Center, Nashville, TN; 2Vanderbilt Univer-
isty Medical Center, Nashville, TN; 3Vanderbilt Univeristy Medical
Center, Nashville, TN.The incidence of new onset PTDM after an allogeneic SCT is un-
known. We conducted a prospective study in patients (pts.) undergo-
ing allogeneic SCT with cyclosporine based graft-versus-host
disease (GVHD) prophylaxis to identify risk factors for PTDM.
Methods: Non diabetic pts. meeting screening criteria were en-
rolled. Demographics including family history, race, past history
of transient diabetes and body-mass index were obtained. Baseline
fasting samples included blood glucose (BG), lipid profile, serum
fructosamine, serum C-peptide and insulin. Pts. had weekly fasting
BG. PTDM was defined by standard criteria. Systemic steroids
(SS) were used to treat GVHD. Results: Median age of pts. (20
males, 17 females) was 43 yrs. (range, 21–66). Median FBG was
97 mg/dL (range, 80–119). 22 of 37 pts. (60%) developed DM at
a median of 41 days post SCT (range, 8–93). 14 of 37 pts (38%)
completed study until day 100 without developing DM and 1 pa-
tient died prior to day 100 without PTDM. In univariate analyses,
the only pre-transplant variable that predicted for PTDM was se-
rum C-peptide and serum insulin levels. Pts. with PTDM had
higher pre-transplant serum C-peptide level compared to pts. with-
out PTDM (4.68, 95% CI 3.76 to 5.66 vs. 2.29, 95% CI 1.87 to
2.71, P\0.0001). Pts. with PTDM had higher mean pre-transplant
serum insulin level compared to pts. without PTDM (22.86, 95%
CI 16.44 to 29.33 vs. 10.57, 95% CI 6.64 to 14, P\ 0.0001). 13
of 21 (61%) pts. who received SS developed PTDM compared
with 9 of 16 (56%) who did not receive SS (P 5 0.729). In a multi-
variable Cox-regression analyses (adjusted for SS use), C-peptide
was an independent predictor of PTDM (HR 1.264; 95% CI
1.06–1.50, P 5 0.008). The interaction between C-peptide and SS
was significant. In subgroup analyses of pts. without SS, C-peptide
had a HR of 1.89 (95% CI 1.16–3.06, P5 0.009), and in pts. with SS
the HR was 1.15 (95% CI 0.94–1.4, P 5 0.161). Conclusion: Our
study shows that PTDM occurs in 60% of pts. after allogeneic SCT
and in 56% of pts. without SS use. Pre-transplant C-peptide level is
an independent risk factor, especially in patients without SS use.
The exact etiology of PTDM in pts. without SS use is not known.
Perhaps, a pre-transplant higher C-peptide level identifies patients
at risk for metabolic stress following allogeneic SCT. It is well es-
tablished that elevated C-peptide and insulin levels are hallmark fea-
tures of insulin resistant states and early type 2 diabetes.291
COMPARISON OF OUTCOMES IN CHILDREN UNDERGOING A SINGLE AL-
LOGENEIC TRANSPLANT USING BONE MARROW (BM) OR UMBILICAL
CORD BLOOD (UCB) AS STEM CELL SOURCE. THE CHILDREN’S MEMO-
RIAL HOSPITAL EXPERIENCE
Merchant, M.1, Huang, W.1, Kletzel, M.1,2. 1Children’s Memorial Hos-
pital, Chicago, IL; 2Northwestern University Feinberg School of Medi-
cine, Chicago, IL.
Objective: To evaluate differences in transplant outcomes be-
tween recipients of BM and UCB. Method: We evaluate 137 trans-
plants with BM and 119 UCB at Children’s Memorial Hospital,
between 1992 and 2007. BM: 122 MR, 15 MUD; 108 pts (78.8%)
had malignancies (ALL n 5 55, AML n 5 31, others n 5 22),
46% were in first complete remission (CR1), 28.5% in $ CR 2,
and 8% in partial remission (PR). 29 (21.2%) had non-malignant
conditions (THAL 5 7, Aplastic Anemia 5 8, SCIDS 5 2, others
5 12). 67.9% received myeloablative conditioning (fTBI, VP-Cy,
or Thiotepa); 32.1% had reduced intensity conditioning (RIC)
(VP/Cy, Bu/FLU/, 6 ATG). 52 female, 85 male; age 9.2 yrs (0.2–
23); weight 30.4 kg (4–85.1). HLA matching, 6/6 (100), 5/6 (28),
4/6 (9). Median TNC infused was 1.96  108/kg, 1.22  108/kg
MNC, 7.45 106/kg CD34. UCB: 82 pts (68.9%) had malignancies
(ALL n5 40, AML n5 24, others n5 18), 36.1% in CR1, 25.2% in
$CR2, 7.6% in PR. 37 pts (31.1%) had non-malignant conditions
(SCIDS n5 11, THAL n5 3, Aplastic Anemia n5 2, others5 21).
79% received myeloablation (fTBI/VP/Cy for malignancies, fTBI/
CY 6Thiotepa for non-malignant); 21% had RIC (VP/Cy or Bu/
FLU/6 ATG). 53 female, 66 male; age 5.4 yrs (0.1–20.6), weight
15.7 kg (4–73). HLA matching 6/6 (12) 5/6 (29) 4/6 (70) 3/6 (8).
Cell dose infused was 0.8  108/kg TNC, 0.55  108/kg MNC,
0.78  06/kg CD34. Result/Outcome: BM: 86.3% achieved
ANC (.500 cells/mL), 88.4% achieved PLT count (.20,000
cells/mL) at median of 18.3 days (10–71) and 32.9 days (4–222)
